ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Pretreatment MRI radiomics for predicting pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBreast cancer’s personalized management requires better risk stratification. Recent studies focus on differentiating the pathological complete response (pCR) from non-pCR, which lacks accuracy in prognostic prediction and therapy guidance for most non-pCR patients. We aimed to better stratify neoadjuvant chemotherapy (NAC) response and early identification of poor responders in the non-pCR population.
methodsPretreatment MRI scans were obtained retrospectively from breast cancer patients who had NAC followed by surgery (January 2021-October 2023). Pathological response to NAC was assessed using the Miller-Payne (MP) grading system, with grades 1–2 indicating poor response and grades 3–5 indicating good response. Logistic regression was used to identify variables associated with MP grading and to build predictive models based on the radiomics score, clinicopathological features, and their combination. Additionally, machine learning models were also trained. The models were assessed for discrimination, calibration, and decision-making ability. Shapley Additive Explanations (SHAP) analysis was specifically performed to interpret the final machine learning model.
resultsA total of 336 patients were included (mean age, 48.75 ± 9.52 years; training set, 235; test set, 101). Radiomics score (OR = 1.46, 95% CI: 1.09, 1.99; P = 0.013) and human epidermal growth factor receptor 2 (HER2) status (OR = 5.93, 95% CI: 2.58, 16.16; P < 0.001) were independently associated with MP grades. The logistic regression, XGBoost, and decision tree combined models demonstrated enhanced discrimination performance, with area under the receiver operating characteristic curve (AUC) of 0.77 (95% CI: 0.67, 0.87), 0.74 (95% CI: 0.65, 0.84), and 0.71(95% CI: 0.59, 0.82), respectively.
conclusionsThe combined model integrating pretreatment MRI radiomics score and HER2 status effectively differentiated between MP grades 1–2 and 3–5 in breast cancer following NAC. The study improved response stratification, with a specific emphasis on early detection of poor NAC responders in order to provide precise prognostic guidance and influence treatment options for this patient population.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.